Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Ahmed Aribi, MD, Anjali S Advani, MD, William Donnellan, MD, Amir T. Fathi, MD, Marcello Rotta, MD, Benjamin K. Tomlinson, MD, Pankit Vachani, MD, Jay Yang, MD, Phoenix Ho, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136203

Published: 2020

Journal Articles

Potential of Sea-CD70 for the Treatment of Myeloid Leukemia

Daniel Diolaiti, PhD, Jane Haass, Michelle Ulrich, Yufei Chen, PhD, Phoenix Ho, MD, Shyra J Gardai, PhD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-140829

Published: 2020

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

C. Michel Zwaan, MD PhD, Stefan Söderhäll, MD PhD, Benoit Brethon, MD, Matteo Luciani, MD, Carmelo Rizzari, MD, David Sternberg, MD PhD, Emmanuelle Besse, Catherine Dutreix, MD, Franca Fagioli, MD, Phoenix Ho, MD, Carlo Dufour, MD, Rob Pieters, MD PhD

Blood (2015) 126 (23): 2564.

https://doi.org/10.1182/blood.V126.23.2564.2564

Published: 2015

Journal Articles

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Kristen Miller, BS, Phoenix Ho, MD, Nyla A. Heerema, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 2614.

https://doi.org/10.1182/blood.V114.22.2614.2614

Published: 2009

NARROW

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Potential of Sea-CD70 for the Treatment of Myeloid Leukemia

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Potential of Sea-CD70 for the Treatment of Myeloid Leukemia

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only